Biogen/Sumitomo licensing agreement
Executive Summary
Two firms announced June 27 they will jointly develop human granulocyte-macrophage colony stimulating factor. DNA-produced natural substance promotes growth of white blood cell populations, and is potentially applicable in immune compromised individuals and in the treatment of resistant infections. Under the agreement, Sumitomo will support Biogen R&D and have exclusive rights to the Japanese market.